Answers are grounded in this paper and cite their sources.
Introduction: Hydrogen breath testing is used to investigate persistent unexplained gastrointestinal symptoms, particularly suspected small intestinal bacterial overgrowth (SIBO). The primary objective of this study was to describe hydrogen breath test utilization in our department and assess the impact of different diagnostic cutoffs on glucose breath test positivity, while secondary exploratory analyses evaluated associations with symptom burden, proton pump inhibitor use, and hydrogen curve dynamics. Methods: This retrospective single-center observational study included 205 patients referred for hydrogen breath testing (methane was not measured). Clinical data were collected using a standardized questionnaire. Glucose or lactulose was used for suspected SIBO, and lactose or fructose for carbohydrate malabsorption. Glucose tests were analyzed using rises of ≥10 ppm and ≥20 ppm above baseline. Results: Glucose was used in 195 patients. Among these tests, 94/195 (48.2%) were positive at the ≥10 ppm cutoff and 59/195 (30.3%) at the ≥20 ppm cutoff. The occurrence of symptoms during testing did not differ significantly between positive and negative tests at either threshold, though numerical trends were observed. However, cumulative symptom burden (total symptom scores) was significantly higher in patients with positive results at both ≥10 ppm [median 10 (IQR 0–30) vs. 1 (IQR 0–15.3), p = 0.008] and ≥20 ppm [median 14 (IQR 1–32) vs. 2 (IQR 0–18.5), p = 0.002]. A larger maximum hydrogen rise was weakly associated with greater symptom burden. PPI use within the previous 6 months showed a non-significant numerical trend toward higher test positivity. Most positive tests reached the diagnostic threshold within the first 60 min. Conclusions: In our center, glucose hydrogen breath testing was used mainly for suspected SIBO. Test positivity varied substantially according to the diagnostic cutoff. While binary symptom occurrence did not differ significantly between groups, the cumulative symptom burden was significantly higher in patients with positive results.
No takes yet. Share an insight, caveat, or question.
David et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: